- Book
- October 2022
- 816 Pages
- Book
- December 2019
- 400 Pages
- Book
- April 2018
- 472 Pages
- Book
- August 2013
- 624 Pages
- Book
- June 2012
- 412 Pages
- Book
- December 2011
- 750 Pages
- Book
- December 2010
- 800 Pages
- Book
- April 2009
- 392 Pages
- Book
- October 2023
- 336 Pages
- Book
- October 2023
- 336 Pages
The Orphan Drug market is a subset of the Pharmaceutical industry that focuses on the development and commercialization of drugs for rare diseases. These drugs are typically developed to treat diseases that affect fewer than 200,000 people in the United States. The Orphan Drug Act of 1983 was passed to incentivize the development of these drugs by providing tax credits, grants, and other incentives to companies that develop them.
The Orphan Drug market has grown significantly in recent years, with more companies entering the market and more drugs being developed. This growth has been driven by advances in medical technology, increased public awareness of rare diseases, and the availability of government incentives.
Some companies in the Orphan Drug market include AbbVie, Amgen, Biogen, Gilead Sciences, and Novartis. Show Less Read more